Vitamin D Products

(off-site)

Donate via PayPal

Your tax-deductable gift will help us to be more effective in our mission to end the worldwide epidemic of vitamin D deficiency.

Vitamin D On The Web

See our Vitamin D News page for all the latest vitamin D headlines from around the globe.

Our Best Vitamin D Articles page for links to informative, less-mainstream articles on vitamin D and UV exposure.

Vitamin D Research

back to research menu

Parkinson's Disease

Osteoporosis in Parkinson's disease. Parkinsonism Relat Disord. 2009 Jun;15(5):339–46. Review.
Pharmacotherapy guidelines for the aged by family doctors for the use of family doctors: Part C Special Pharmacology. Int J Clin Pharmacol Ther. 2009 Mar;Volume 47(March):141–152.
Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008 Oct;65(10):1348–52.
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008 Apr;129(4):526–9.
Bone mass in elderly patients with Parkinson's disease. Acta Neurol Scand. 2007 Oct;116(4):248–54.
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology. 2007 Mar 20;68(12):911–5.
Vitamin D and Parkinson's disease—a hypothesis. Mov Disord. 2007 Mar 15;22(4):461–8.
Body weight in patients with Parkinson's disease. Mov Disord. 2006 Nov;21(11):1824–30. Review.
Immunodetection of heparin-binding growth associated molecule (pleiotrophin) in striatal interneurons. Brain Res. 2005 Dec 20;1066(1–2):196–200.
Parkinson's disease and osteoporosis. Joint Bone Spine. 2005 Dec;72(6):484–8.
Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients. Mov Disord. 2005 Dec;20(12):1598–603.
Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J Neurosci. 2005 Jul 6;25(27):6467–77.
Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain. 2005 Jul;128(Pt 7):1498–510.
Association of vitamin D receptor gene polymorphism and Parkinson's disease in Koreans. J Korean Med Sci. 2005 Jun;20(3):495–8.
Sarcoidosis succumbs to antibiotics—implications for autoimmune disease. Autoimmun Rev. 2004 Jun;3(4):295–300. Review.
Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab. 2003 Dec;88(12):5650–5.
Body composition in advanced-stage Parkinson's disease. Acta Diabetol. 2003 Oct;40 Suppl 1:S187–90.
Alpha-synuclein accumulates in Purkinje cells in Lewy body disease but not in multiple system atrophy. J Neuropathol Exp Neurol. 2003 Aug;62(8):812–9.
Diet and Parkinson's disease: a potential role of dairy products in men. Ann Neurol. 2002 Dec;52(6):793–801.
Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency. Bone. 2002 Jul;31(1):114–8.
Niemann-Pick disease type B: an unusual clinical presentation with multiple vertebral fractures. Am J Med Genet. 2002 Apr 15;109(1):42–51.
Vitamin K deficiency and osteopenia in vitamin D-deficient elderly women with Parkinson's disease. Arch Phys Med Rehabil. 2002 Jan;83(1):86–91.
Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res. 2001 Jun 15;904(1):67–75.
Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease. Exp Neurol. 2001 May;169(1):163–81.
Micronutrient accumulation and depletion in schizophrenia, epilepsy, autism and Parkinson's disease? Med Hypotheses. 2001 May;56(5):641–5.
Expression of calbindin D28K in the dopaminergic mesotelencephalic system in embryonic and fetal human brain. J Comp Neurol. 2001 Jan 1;429(1):45–58.
Additive effect of glial cell line-derived neurotrophic factor and neurotrophin-4/5 on rat fetal nigral explant cultures. Neuroscience. 2001;108(2):273–84.
The expression of the calcium binding protein calretinin in the rat striatum: effects of dopamine depletion and L-DOPA treatment. Exp Neurol. 2000 Aug;164(2):322–32.
Calretinin-containing axons and neurons are resistant to an intrastriatal 6-hydroxydopamine lesion. Brain Res. 2000 Jun 2;866(1–2):55–64.
Relationships among diet, physical activity and other lifestyle factors and debilitating diseases in the elderly. Eur J Clin Nutr. 2000 Jun;54 Suppl 3:S143–7. Review.
Relative sparing of calretinin containing neurons in the substantia nigra of 6-OHDA treated rat Parkinsonian model. Brain Res. 2000 Feb 7;855(1):162–5.
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999 Aug;122 ( Pt 8):1437–48.
The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain. 1999 Aug;122 ( Pt 8):1421–36.
'Like a thief in the night': the selectivity of degeneration in Parkinson's disease. Brain. 1999 Aug;122 ( Pt 8):1401–2. Review.
Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999 Jan;66(1):64–8.
Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov Disord. 1999 Jan;14(1):21–7.
Localization of calcium-binding proteins and GABA transporter (GAT-1) messenger RNA in the human subthalamic nucleus. Neuroscience. 1999 Jan;88(2):521–34.
Efferent synaptic connections of dopaminergic neurons grafted into the caudate nucleus of experimentally induced parkinsonian monkeys are different from those of control animals. Exp Brain Res. 1998 Dec;123(3):323–33.
High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology. 1997 Nov;49(5):1273–8.
Reversible parkinsonism, hypophosphoremia, and hypocalcemia under vitamin D therapy. Mov Disord. 1997 Jul;12(4):612–3.
The subthalamic nucleus in Parkinson's disease and progressive supranuclear palsy. J Neuropathol Exp Neurol. 1997 Feb;56(2):132–42.
Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Ann N Y Acad Sci. 1995 Sep 15;765:236–47; discussion 248. Review.
Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease? Brain Res. 1994 Dec 30;668(1–2):62–70.
Sparing of the dopaminergic neurons containing calbindin-D28k and of the dopaminergic mesocortical projections in weaver mutant mice. Neuroscience. 1994 Jul;61(2):293–305.
Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp Neurol. 1994 Apr;126(2):195–204.
The organotypic entorhinal-hippocampal complex slice culture of adolescent rats. A model to study transcellular changes in a circuit particularly vulnerable in neurodegenerative disorders. J Neural Transm Suppl. 1994;44:61–71.
Levodopa-responsive parkinsonism associated with basal ganglia calcification and primary hypoparathyroidism. Mov Disord. 1993 Jul;8(3):398–400.
The heterogeneity of the mesostriatal dopaminergic system as revealed in normal and parkinsonian monkeys. Adv Neurol. 1993;60:25–33.
Calbindin D-28k and monoamine oxidase A immunoreactive neurons in the nucleus basalis of Meynert in senile dementia of the Alzheimer type and Parkinson's disease. Dementia. 1993 Jan–Feb;4(1):1–15.
Calbindin-D28k in the basal ganglia of patients with parkinsonism. Ann Neurol. 1992 Oct;32(4):543–50.
Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res. 1992 May 29;581(2):283–91.
Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci. 1992 May 11;648:42–62.
Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys. Neuroreport. 1991 Oct;2(10):601–4.
Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 1990 Sep 3;526(2):303–7.
Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4078–82.
Effects of elevated lead and cadmium burdens on renal function and calcium metabolism. Arch Environ Health. 1986 Mar–Apr;41(2):69–76.
Calcium and vitamin D metabolism in Guamanian Chamorros with amyotrophic lateral sclerosis and parkinsonism-dementia. Ann Neurol. 1984 Jan;15(1):42–8.
Vitamin D metabolites and analogues, diphosphonates, danazol, and bromocriptine. Br Med J (Clin Res Ed). 1983 May 21;286(6378):1625–8.
Diogenes syndrome. A clinical study of gross neglect in old age. Lancet. 1975 Feb 15;1(7903):366–8.
New data on monoamine oxidase inhibitors. Vestn Akad Med Nauk SSSR. 1971;26(11):23–8. Review.

back to research menu

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Unless otherwise expressly stated, all site content licensed under a Creative Commons License.